Both RNA interference (RNAi)-mediated BRD9 knockdown and CRISPR-Cas9-mediated BRD9 knockout compromised the proliferation of SMARCB1-mutant MRT cells, providing compelling support that BRD9 is a therapeutic target for SMARCB1-mutated cancers [81,82]. The gene discussed is SMARCB1; the disease is cancer.